Biotech Stock News (THLD) (BLUE) (SYN)

Threshold Pharmaceuticals (NASDAQ:THLD) On Monday December 7, 2015 shares of Threshold Pharmaceuticals fell 82% after the company announced the failure of two phase 3 clinical trials. The two phase 3 clinical trials were MAESTRO and TH-CR-406/SARC021. Each phase 3 trial was treating a different indication, but used the company’s drug Evofosfamide together with some type … Read more